source
- ProMIS Neurosciences early trial shows low brain bleeding and no swelling, hinting at safer Alzheimer’s drugProMIS Neurosciences reported interim safety data from a early‑stage trial of its amyloid‑targeting therapy for Alzheimer’s disease. The analysis pooled data from participants receiving the investi…
- Dementia finally shows a viable business model, AAIC2026 highlights economic shiftAt the Alzheimer’s Association International Conference in London this year, the author observed that dementia now appears to have a clear business model, a shift from earlier meetings where commer…